Luteolin for Allergy & Mast-Cell Stabilization

Mast cells are the cells behind allergy: they store histamine and other inflammatory mediators and release them in a burst when triggered, producing the sneezing, itching, congestion, and swelling of an allergic reaction. Luteolin is one of the most studied natural “mast-cell stabilizers” — molecules that make mast cells harder to trigger. In cell studies the evidence is striking: one 2024 study found luteolin more potent than the prescription mast-cell drug cromolyn at blocking mediator release from human mast cells. That laboratory story is genuinely strong. The human clinical story is much thinner, resting largely on cell and animal work plus limited trials, so this page keeps the promising mechanism and the modest human evidence clearly apart.

Table of Contents

  1. What Mast Cells Are and Why They Matter
  2. How Luteolin Stabilizes Mast Cells
  3. More Potent Than Cromolyn: The 2024 Finding
  4. Histamine, Tryptase, and the Other Mediators
  5. Allergic Rhinitis and Sinus Symptoms
  6. Asthma and Airway Inflammation
  7. Mast Cell Activation Syndrome
  8. Where the Human Evidence Actually Stands
  9. Practical Notes
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Mast Cells Are and Why They Matter

Mast cells are immune cells stationed in the tissues that meet the outside world — skin, nose, sinuses, lungs, and gut. Each mast cell is packed with granules full of pre-made inflammatory chemicals, most famously histamine. When an allergen cross-links the IgE antibodies bound to the mast cell's surface (through a receptor called FcεRI), the cell degranulates: it dumps histamine, tryptase, prostaglandins, and leukotrienes into the surrounding tissue within seconds. That release is what you feel as an allergic reaction — itch, swelling, congestion, hives, wheeze.

Mast cells can also be triggered without IgE, through other receptors such as MRGPRX2 (relevant to some drug reactions and non-allergic hypersensitivity). A “mast-cell stabilizer” is any agent that raises the threshold for this degranulation, so the cell releases less, or not at all, when triggered. The prescription drug cromolyn (cromoglicate) works this way, and luteolin is one of the natural molecules studied for the same effect.

Back to Table of Contents

How Luteolin Stabilizes Mast Cells

Luteolin acts on the internal signaling that a mast cell uses to decide whether to degranulate. The key steps it interferes with:

The result in the laboratory is a mast cell that releases substantially less histamine, tryptase, and prostaglandin D2 when challenged. Because luteolin hits both the IgE pathway and the MRGPRX2 pathway, it is of interest for both classic allergy and non-IgE hypersensitivity.

Back to Table of Contents

More Potent Than Cromolyn: The 2024 Finding

The most striking recent result comes from Tsilioni and colleagues (2024), who compared luteolin directly against cromolyn — the standard prescription mast-cell stabilizer — using cultured human mast cells. Luteolin was more potent than cromolyn at inhibiting the release of inflammatory mediators. This matters because cromolyn, while safe, is notoriously weak and poorly absorbed in practice; a natural molecule outperforming it in a controlled comparison is a meaningful laboratory finding.

The honest framing: this is a cultured-cell study, not a clinical trial. “More potent than cromolyn in a dish” is a strong signal that luteolin is a genuine mast-cell stabilizer, but it does not by itself prove that swallowing luteolin will relieve a person's allergy symptoms — that depends on how much luteolin actually reaches the mast cells in tissue, which is limited by its poor absorption (see Sources). It is the reason luteolin is a serious research candidate, and the reason properly designed human trials are the missing piece.

Back to Table of Contents

Histamine, Tryptase, and the Other Mediators

The earliest and still among the clearest human-cell data come from Kimata and colleagues (2000), who tested luteolin, quercetin, and baicalein on IgE-triggered human mast cells and found that all three flavonoids reduced the release of histamine and the synthesis of leukotrienes and prostaglandin D2. In other words, luteolin does not just block histamine — it reduces the whole spectrum of mast-cell mediators, including the ones ordinary antihistamine drugs do not touch.

This broader action is why flavonoid mast-cell stabilizers are conceptually different from antihistamines. An antihistamine blocks the histamine receptor after histamine is released; a stabilizer like luteolin reduces the release of histamine and tryptase, prostaglandins, and leukotrienes in the first place. On paper that is a more upstream, more complete approach — with the same crucial asterisk that the human clinical evidence has not caught up to the mechanism.

Back to Table of Contents

Allergic Rhinitis and Sinus Symptoms

Allergic rhinitis — the runny, congested, sneezy nose of hay fever — is driven directly by nasal mast-cell degranulation, so it is the most obvious target for a mast-cell stabilizer. In an animal model of allergic rhinitis, Guo and colleagues (2025) reported that luteolin reduced nasal allergic symptoms and helped correct the underlying T-cell subset imbalance that sustains the allergic response.

These are animal data. They fit the mechanism neatly and make luteolin a reasonable adjunct to consider, but no large controlled trial has shown that luteolin relieves human hay fever, and it should not replace proven treatments such as intranasal corticosteroids or antihistamines for people with significant symptoms. For the condition itself, see Allergic Rhinitis.

Back to Table of Contents

Asthma and Airway Inflammation

Asthma involves both mast-cell activation and a broader eosinophilic, Th2-skewed airway inflammation. Luteolin has been tested in animal asthma models with encouraging results. Kim and colleagues (2018) found that luteolin attenuated airway inflammation in part by promoting the development of regulatory T cells (shifting CD4+CD25− cells toward the CD4+CD25+ regulatory phenotype), which helps restrain the allergic response at its source rather than only blocking a single mediator.

As with rhinitis, this is preclinical. Asthma is a potentially dangerous condition, and luteolin is not a substitute for controller inhalers or rescue medication. Its role, if any, would be as a dietary adjunct in a comprehensive plan — and even that is not yet proven in trials. See Asthma for evidence-based management.

Back to Table of Contents

Mast Cell Activation Syndrome

Mast Cell Activation Syndrome (MCAS) is a condition of inappropriate, excessive mast-cell mediator release causing multi-system symptoms — flushing, hives, gut upset, brain fog, and more. Because luteolin stabilizes mast cells, it is one of the flavonoids frequently used in MCAS management as an adjunct to prescription stabilizers and antihistamines, and it appears among natural mast-cell stabilizers that some clinicians and patients incorporate into a broader regimen.

The evidence base here is largely mechanistic plus clinical experience rather than randomized trials, so luteolin should be viewed as a reasonable, low-risk adjunct to discuss with a knowledgeable clinician — not a proven standalone therapy. See Mast Cell Activation Syndrome, the closely related Mastocytosis, and the overview of Natural Mast-Cell Stabilizers.

Back to Table of Contents

Where the Human Evidence Actually Stands

Pulling it together honestly:

So luteolin is a well-supported mast-cell stabilizer in the laboratory and a plausible, low-risk dietary adjunct in practice — but not a proven replacement for standard allergy or asthma treatment.

Back to Table of Contents

Practical Notes

Back to Table of Contents

Key Research Papers

  1. Tsilioni I et al. (2024). Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells. International Archives of Allergy and Immunology. — PubMed 38588651
  2. Kimata M et al. (2000). Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clinical & Experimental Allergy. — PubMed 10718847
  3. Hao Y et al. (2022). Luteolin inhibits FcεRI- and MRGPRX2-mediated mast cell activation by regulating calcium signaling. Phytotherapy Research. — PubMed 35315143
  4. Kritas SK et al. (2013). Luteolin inhibits mast cell-mediated allergic inflammation. Journal of Biological Regulators and Homeostatic Agents. — PubMed 24382176
  5. Kim SH et al. (2018). Luteolin attenuates airway inflammation by inducing the transition of CD4+CD25− to CD4+CD25+ regulatory T cells. European Journal of Pharmacology. — PubMed 29225189
  6. Guo X et al. (2025). Luteolin Ameliorates Allergic Rhinitis in Mice through Modulating T Cell Subset Imbalance. Iranian Journal of Allergy, Asthma and Immunology. — PubMed 40471643
  7. Seelinger G et al. (2008). Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Medica. — PubMed 18937165
  8. Theoharides TC et al. (2019). Recent advances in our understanding of mast cell activation. Expert Review of Clinical Immunology. — PubMed 30884251
  9. Yamashita S et al. (2016). A novel in vitro co-culture model comprised of Caco-2/RBL-2H3 cells to evaluate anti-allergic effects of food components. Journal of Immunological Methods. — PubMed 27131754
  10. Kang TK et al. (2026). Anti-Allergic Potential of Chamaecrista nomame and Its Compound Luteolin for Novel Asthma Therapy. Phytotherapy Research. — PubMed 42084904

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents